Zacks Investment Research upgraded shares of BRENNTAG AG/ADR (OTCMKTS:BNTGY) from a hold rating to a buy rating in a research report report published on Tuesday morning, Zacks.com reports. Zacks Investment Research currently has $12.00 target price on the stock.
According to Zacks, “Brenntag AG engages in the production and distribution of chemicals. It operates through the North America, Latin America, EMEA and Asia Pacific segments. Brenntag AG is headquartered in Mülheim an der Ruhr, Germany. “
A number of other equities analysts have also weighed in on the stock. ValuEngine upgraded shares of BRENNTAG AG/ADR from a sell rating to a hold rating in a research report on Friday, March 15th. Goldman Sachs Group upgraded shares of BRENNTAG AG/ADR from a neutral rating to a buy rating in a research report on Monday, January 21st.
BRENNTAG AG/ADR (OTCMKTS:BNTGY) last issued its earnings results on Wednesday, March 6th. The company reported $0.18 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.03. The firm had revenue of $3.58 billion during the quarter. BRENNTAG AG/ADR had a net margin of 3.67% and a return on equity of 14.35%. On average, sell-side analysts expect that BRENNTAG AG/ADR will post 0.69 EPS for the current fiscal year.
The firm also recently announced an annual dividend, which will be paid on Wednesday, July 3rd. Shareholders of record on Monday, June 17th will be given a dividend of $0.175 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a yield of 1.6%. BRENNTAG AG/ADR’s dividend payout ratio is presently 24.29%.
BRENNTAG AG/ADR Company Profile
Brenntag AG, a chemical distribution company, purchases and supplies industrial and specialty chemicals in Europe, the Middle East, Africa, North America, Latin America, the Asia Pacific, and internationally. The company also provides value added services. It serves customers in various end-market industries, such as adhesives, paints, oil and gas, food, water treatment, personal care, and pharmaceuticals.
Recommended Story: Outstanding Shares and The Effect on Share Price
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BRENNTAG AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRENNTAG AG/ADR and related companies with MarketBeat.com's FREE daily email newsletter.